Device Incident Reporting — EU MDR Vigilance and FDA MedWatch/MAUDE

Once a device incident is identified, the reporting pathway that follows is structurally similar to the expedited drug reporting timelines Module 1 built, adapted for the device-specific vocabulary Lesson 14.8 introduced. In the EU, the MDR vigilance system requires manufacturers to report a "serious incident" — any malfunction or deterioration in a device’s characteristics or performance that led, or might have led, to death, serious deterioration in health, or a serious public health threat. The timeline scales with urgency exactly the way Module 1’s SUSAR timelines did: an immediate report within 2 days for a serious public health threat, 10 days for death or an unanticipated serious deterioration in health, and 15 days for other serious incidents.

The US system runs through FDA’s MedWatch programme, with mandatory reporting obligations on manufacturers, importers, and device user facilities for a "reportable event" — death or serious injury a device may have caused or contributed to, or a malfunction that would likely cause death or serious injury if it recurred. Standard manufacturer reports are due within 30 calendar days, with a compressed 5-day timeline for certain events requiring immediate remedial action — again, the same underlying principle Module 1 established: the more urgent the potential harm, the tighter the clock.

Both systems feed into public-facing databases that function, in effect, like a public-searchable version of the safety databases Module 10 covered in depth for drugs. EUDAMED, the European Database on Medical Devices, includes a vigilance module tracking reported incidents. MAUDE — the Manufacturer and User Facility Device Experience database — is FDA’s equivalent, and it’s genuinely, directly searchable by researchers, journalists, and the public, not just regulators, which gives device vigilance a transparency dimension that’s somewhat more immediate than the equivalent drug safety databases.

One additional obligation worth knowing specifically: manufacturers in the EU system must also report trends — patterns of non-serious incidents, or even expected side effects, that could collectively and significantly change a device’s benefit-risk determination even though no single incident in the pattern would individually trigger a serious-incident report. This is device vigilance’s direct equivalent of Module 7’s signal detection discipline: individually unremarkable events, examined in aggregate, can reveal a pattern that matters — the same underlying logic, applied to a genuinely different regulatory framework and product category.